Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
WXXWY WUXI BIOLGCS ADR
12.040
-0.370-2.98%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(FY)2020/12/31(FY)2019/12/31(FY)2018/12/31
Total revenue
83.35% 10.29B 40.88% 5.61B 57.18% 3.98B 56.56% 2.53B
Operating revenue
83.35% 10.29B 40.88% 5.61B 57.18% 3.98B 56.56% 2.53B
Cost of revenue
77.34% 5.46B 32.46% 3.08B 53.28% 2.32B 58.27% 1.52B
Gross profit
90.64% 4.83B 52.70% 2.53B 62.99% 1.66B 54.08% 1.02B
Operating expense
76.84% 1.36B 28.19% 771.43M 85.95% 601.77M 44.52% 323.62M
Selling and administrative expenses
65.15% 1B 36.34% 605.85M 64.49% 444.37M 67.13% 270.15M
-Selling and marketing expense
32.02% 124.65M 22.49% 94.42M 81.66% 77.08M 53.61% 42.43M
-General and administrative expense
71.27% 875.93M 39.25% 511.44M 61.29% 367.29M 69.92% 227.72M
Research and development costs
65.14% 501.58M 16.98% 303.73M 53.38% 259.65M 127.29% 169.29M
Operating profit
96.68% 3.46B 66.64% 1.76B 52.28% 1.06B 58.97% 694.14M
Net non-operating interest income expense
-50.61% 18.84M -13.83% 38.13M -43.55% 44.25M 390.94% 78.39M
Non-operating interest income
-28.24% 58.03M 26.63% 80.86M -18.54% 63.86M 796.34% 78.39M
Non-operating interest expense
-8.29% 39.19M 117.96% 42.73M -- 19.61M -- 0
Other net income (expense)
Special income (charges)
-29.41% -156.67M -1,669.39% -121.06M 87.77% -6.84M -246.53% -55.94M
-Write off
29.41% 156.67M 1,669.39% 121.06M -87.77% 6.84M -- 55.94M
Other non- operating income (expenses)
-80.91% 837K 322.43% 4.38M -173.65% -1.97M 17.11% 2.68M
Income before tax
103.13% 3.99B 74.48% 1.97B 52.72% 1.13B 142.92% 737.72M
Income tax
77.44% 484.54M 134.80% 273.07M 8.43% 116.3M 110.06% 107.26M
Net income
107.28% 3.51B 67.54% 1.69B 60.25% 1.01B 149.56% 630.47M
Net income continuous Operations
107.28% 3.51B 67.54% 1.69B 60.25% 1.01B 149.56% 630.47M
Minority interest income
3,053.97% 120.1M 209.80% 3.81M -2,630.71% -3.47M -127K
Net income attributable to the parent company
100.63% 3.39B 66.59% 1.69B 60.77% 1.01B 149.61% 630.59M
Preferred stock dividends
Other preferred stock dividends
0 0 0 0
Net income attributable to common stockholders
100.63% 3.39B 66.59% 1.69B 60.77% 1.01B 149.61% 630.59M
Basic earnings per share
88.37% 1.62 57.32% 0.86 57.69% 0.5467 550.00% 0.3467
Diluted earnings per share
92.50% 1.54 57.89% 0.8 58.33% 0.5067 554.54% 0.32
Dividend per share
Currency Unit
CNYCNYCNYCNY

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug substance cGMP manufacture; commercial drug substance cGMP manufacture; drug product cGMP fill and finish; antibody drug conjugates; regulatory affairs; and technologies and platforms. The company was founded on May 24, 2010 and is headquartered in Wuxi, China.
CEO: Dr. Chen Zhisheng
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist